CL2021001976A1 - Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular - Google Patents

Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular

Info

Publication number
CL2021001976A1
CL2021001976A1 CL2021001976A CL2021001976A CL2021001976A1 CL 2021001976 A1 CL2021001976 A1 CL 2021001976A1 CL 2021001976 A CL2021001976 A CL 2021001976A CL 2021001976 A CL2021001976 A CL 2021001976A CL 2021001976 A1 CL2021001976 A1 CL 2021001976A1
Authority
CL
Chile
Prior art keywords
pruritus
treatment
patients
skin lesions
prurigo
Prior art date
Application number
CL2021001976A
Other languages
English (en)
Inventor
Christophe Piketty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2021001976A1 publication Critical patent/CL2021001976A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen métodos para tratar selectivamente el prurito en un sujeto que tiene prurigo crónico (CP), que incluye prurigo nodular (PN), composición farmacéuticas para usar en el tratamiento de prurito en un sujeto que tiene CP o PN, usos de nemolizumab o un equivalente de este en la fabricación de un medicamento para el tratamiento de prurito en un sujeto que tiene CP o PN
CL2021001976A 2019-01-28 2021-07-27 Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular CL2021001976A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US201962809404P 2019-02-22 2019-02-22

Publications (1)

Publication Number Publication Date
CL2021001976A1 true CL2021001976A1 (es) 2022-02-11

Family

ID=69467604

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001976A CL2021001976A1 (es) 2019-01-28 2021-07-27 Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular

Country Status (15)

Country Link
US (2) US11236157B2 (es)
EP (1) EP3917617A1 (es)
JP (4) JP7410852B2 (es)
KR (1) KR102953189B1 (es)
CN (1) CN113660981A (es)
AU (2) AU2020213978A1 (es)
BR (1) BR112021014854A2 (es)
CA (1) CA3127983A1 (es)
CL (1) CL2021001976A1 (es)
IL (1) IL285171B2 (es)
MX (1) MX2021009051A (es)
PH (1) PH12021551805A1 (es)
SG (1) SG11202108220YA (es)
TW (1) TWI861052B (es)
WO (1) WO2020157636A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021359068A1 (en) * 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
WO2023044313A1 (en) * 2021-09-15 2023-03-23 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
US20240141050A1 (en) * 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA3199034C (en) 2015-08-24 2025-09-09 Dmk Pharmaceuticals Corporation SYRINGE-TYPE DEVICES
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Also Published As

Publication number Publication date
JP7410852B2 (ja) 2024-01-10
PH12021551805A1 (en) 2022-07-18
JP2022028788A (ja) 2022-02-16
JP2023182834A (ja) 2023-12-26
TW202043282A (zh) 2020-12-01
MX2021009051A (es) 2021-12-10
JP2021509103A (ja) 2021-03-18
CA3127983A1 (en) 2020-08-06
JP2023126909A (ja) 2023-09-12
KR102953189B1 (ko) 2026-04-15
US20220177568A1 (en) 2022-06-09
JP7671822B2 (ja) 2025-05-02
US20200239563A1 (en) 2020-07-30
IL285171B1 (en) 2025-11-01
TWI861052B (zh) 2024-11-11
AU2020213978A1 (en) 2021-09-23
JP7375252B2 (ja) 2023-11-07
WO2020157636A1 (en) 2020-08-06
US11236157B2 (en) 2022-02-01
CN113660981A (zh) 2021-11-16
KR20210122286A (ko) 2021-10-08
BR112021014854A2 (pt) 2021-12-21
IL285171B2 (en) 2026-03-01
IL285171A (en) 2021-09-30
AU2025263803A1 (en) 2025-11-27
SG11202108220YA (en) 2021-08-30
JP7309816B2 (ja) 2023-07-18
EP3917617A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MX2019003134A (es) Terapia de combinacion.
GT201700246A (es) Métodos y kits para tratar la depresión
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2020009773A (es) Terapia de combinacion.
MX388408B (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
CO2022000270A2 (es) Inhibidores de enzimas
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
MX390755B (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2018016332A (es) Quimioterapias de combinacion.
AR115790A1 (es) Apirasas solubilizadas, métodos y usos
MX2021004463A (es) Terapia de disminución de arginina para el tratamiento de la deficiencia de gamt.
MX390751B (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.